Major Immutep investors including Regal Partners are nursing significant losses after the lung cancer therapy developer abandoned clinical trials, wiping more than $500 million from its market valuation.
Immutep had touted Efti as a potential blockbuster medication that would allow patients with lung cancer to live longer but said on Friday it would scrap trials on the recommendation of an independent committee.
